Influence of danazol and goserelin on insulin and glucagon in non-obese women with endometriosis

Golland, I. M.; Vaughan-Williams, C. A.; Shalet, SM; Laing, Ian; Elstein, Max

doi:10.1530/acta.0.1230405

Cited by 12 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results suggest that as concentrations of total testosterone and androstenedione increase, those of glucagon decrease, a pattern of response opposite to that proposed or which has been identified in other hyperglucagonaemic states. These data do not establish whether testosterone and androstenedione directly influence concentrations of glucagon in plasma, although we have been unable to show any correlation between changes in the concentrations of total or free testosterone or androstenedione and those of glucagon associated with the administration of either danazol or goserelin (Golland et al, 1990).…”

Section: Discussioncontrasting

confidence: 72%

Glucagon in Women With Polycystic Ovary Syndrome (Pco): Relationship to Abnormalities of Insulin and Androgens

Golland¹,

Williams

Shalet³

et al. 1990

Clinical Endocrinology

Self Cite

View full text Add to dashboard Cite

SUMMARY To investigate the glucagon status of women with polycystic ovary syndrome (PCO) and to relate this to serum concentrations of insulin, androgens and SHBG, 44 women with PCO and 23 control subjects underwent a 75‐g oral glucose tolerance test. Although obese (body mass index > 30kg/m2) women with PCO had higher concentrations of glucose and insulin than overweight (BMI 25‐30kg/m2) and non‐obese (BMI <25kg/m2) women with PCO and control subjects, fasting and summed values of glucagon in response to oral glucose were similar in all groups. The fasting and summed concentrations of glucagon were inversely related to those of testosterone and androstenedione in obese women with PCO, but no other relationships were demonstrated between hormone values and those of glucagon in the other groups. We conclude that glucagon is not implicated in peripheral insulin resistance in women with PCO.

show abstract

Section: Discussioncontrasting

confidence: 72%

Glucagon in Women With Polycystic Ovary Syndrome (Pco): Relationship to Abnormalities of Insulin and Androgens

Golland¹,

Williams

Shalet³

et al. 1990

Clinical Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Women with ovarian hyperandrogenism frequently have hyperinsulism with insulin resistance [38,39]. Administration of androgens or ana bolic steroids has been found to decrease insulin sensitiv ity and impair glucose tolerance [40][41][42][43].…”

Section: Discussionmentioning

confidence: 99%

Recombinant Human Growth Hormone and Oxandrolone in Treatment of Short Stature in Girls with Turner Syndrome

Stahnke¹,

Stubbe²,

Keller³

1992

Horm Res

View full text Add to dashboard Cite

91 girls with Turner syndrome (TS) with a mean chronological age (CA) and bone age (BA) of 10.3 ± 2.3 and 8.9 ± 1.9 years, respectively, were randomly assigned to subcutaneous treatment with recombinant human growth hormone (rhGH) alone (n = 47), 2.6 IU/m² body surface area daily or combination treatment (n = 44) with the same dose of rhGH and oxandrolone 0.1 mg/kg body weight orally, for the first 12 months of this study. During the 1 st year of therapy, there was a striking increase in height velocity (HV) in both groups, from 4.0 ± 0.8 to 6.3 ± 1.3 cm/year [HV standard (standards of untreated Turner patients) deviation score (SDS) for CA from 0.0 ± 0.7 to 2.9 ± 1.3] in the rhGH group and from 4.2 ± 1.2 to 8.5 ± 1.7 cm/year (HV SDS-CA from +0.3 ± 1.0 to+5.6 ± 1.6) in the combination group. The difference between the groups was statistically significant (p < 0.01). During the 2nd year of treatment, the rhGH dose was increased to 3.4 IU/m² daily for the rhGH-alone group, whereas in the combination treatment group the oxandrolone dose was reduced to 0.05 mg/kg daily. HV was maintained at significantly higher levels than those prior to treatment, at 5.3 ± 1.1 cm/year (HV SDS-CA:+2.1 ± 1.3) and 6.2 ± 1.5 cm/year (HV SDS-CA:+3.6 ± 1.4) in the rhGH-alone and the combination group, respectively (p < 0.001). After 2 years of treatment, the mean predictable adult height had increased by +3.6 ± 2.4 cm in the rhGH-alone group and by +5.3 ± 3.6 cm in the combination group. Both treatment regimens were very well tolerated although clitoral enlargement was seen in 15 of the 44 girls of the combination group who had been treated with 0.1 mg oxandrolone daily for the 1 st year. Impaired glucose tolerance was infrequently seen in girls of either group and the higher oxandrolone dose of the 1st year affected serum lipoprotein levels. Our data suggest that rhGH may improve adult height in girls with TS. This beneficial effect may be further increased by the addition of a low dose of oxandrolone (0.05 mg/kg/day).

show abstract

“…We have found that long-term therapy leads to a significant decrease in serum SHBG levels over time. This may be the result of a drug-induced decrease in ovar ian estrogen production, given that it is known that estro gen stimulate SHBG synthesis in the liver [21], However, the goserelin-induced decrease in SHBG seems to be a delayed effect, because no change has been observed in the serum SHBG levels of nonobese women with endome triosis after 6 weeks of therapy [22],…”

Section: Time On Treatment Weeksmentioning

confidence: 99%

Goserelin in Premenopausal Advanced Breast Cancer: Clinical and Endocrine Evaluation of Responsive Patients

Bajetta¹,

Zilembo²,

Buzzoni³

et al. 1994

Oncology

View full text Add to dashboard Cite

Medical ovariectomy with goserelin is an alternative to surgical oophorectomy. To evaluate the relationship between tumor regression and endocrine changes induced by therapy, 40 premenopausal patients with advanced breast cancer were given 3.6 mg of goserelin subcutaneously fortnightly for the first 4 doses and every 28 days thereafter. We have made a particular analysis of the clinical and endocrine profile of responsive patients. Objective responses were observed in 17 of the 38 evaluable patients (45%), 6 cases achieving complete remission. Serum estradiol was suppressed in castrated women, although there was a tendency towards an increase in serum follicle-stimulating hormone over time. No statistically significant difference was observed in the hormonal profiles of patients experiencing a complete or partial response. Our experience confirms that goserelin is as effective as oophorectomy and that there is a clear correspondence between clinical response and drug-induced estrogen suppression.

show abstract

Influence of danazol and goserelin on insulin and glucagon in non-obese women with endometriosis

Cited by 12 publications

References 15 publications

Glucagon in Women With Polycystic Ovary Syndrome (Pco): Relationship to Abnormalities of Insulin and Androgens

Glucagon in Women With Polycystic Ovary Syndrome (Pco): Relationship to Abnormalities of Insulin and Androgens

Recombinant Human Growth Hormone and Oxandrolone in Treatment of Short Stature in Girls with Turner Syndrome

Goserelin in Premenopausal Advanced Breast Cancer: Clinical and Endocrine Evaluation of Responsive Patients

Contact Info

Product

Resources

About